This summary provides actionable guidance for configuring an AI agent within the MOTION-OA 301 protocol. ### **1. Core Regulatory and Operational Guidelines** * **Role Limitation:** The AI is an administrative tool, not a medical professional. It cannot provide medical advice, interpret health status, or suggest treatment changes. * **Participant Autonomy:** The participant’s explicit report is authoritative. AI-derived signals (voice dissonance) cannot override, reinterpret, or silently overwrite a patient’s chosen response. * **Data Provenance:** All interactions must maintain a complete audit trail (timestamps, original vs. revised responses, intervention triggers, and agent messages). * **Compliance:** Systems must align with FDA guidance on digital health technologies (fit-for-purpose, validation, security) and ICH E6(R3) standards. ### **2. Question-Level Voice Expression Analysis** * **Purpose:** Exploratory only. Signals represent probabilistic expression/prosody and do not constitute clinical diagnoses or truth-detection. * **Constraint:** These signals may *trigger* a clarification dialogue, but they must not be used to score pain or efficacy. * **Ethical Safeguard:** Avoid stigmatizing labels. Ensure participants understand that the technology analyzes expressive cues and does not detect "internal emotions." ### **3. Closed-Loop Intervention Agent Logic** The Intervention Agent activates only when a predefined "dissonance flag" or error occurs. Its behavior is strictly defined: * **Trigger Categories:** * **Comprehension:** Participant confusion or off-topic responses. * **Content Mismatch:** Recall-period errors, wrong index-joint references, or "response contradictions" (where speech conflicts with the selected answer). * **Safety:** Spontaneous reports of adverse events or urgent medical concerns. * **Permitted Behaviors:** * Neutral repetition of authorized questions or options. * Confirmation of the intended response. * Routing of clinical/safety concerns to a human professional. * **Prohibited Behaviors:** * Coaching, leading, or interpreting pain severity based on voice. * Diagnostic or predictive commentary. * Changing responses without explicit participant confirmation. ### **4. Safety Monitoring and Escalation** * **Escalation Triggers:** Any mention of new/worsening symptoms, hospitalization, emergency care, or request for medical guidance requires immediate routing to a human study professional. * **Emergency Protocol:** The agent must not attempt to manage crises (e.g., life-threatening events) through conversation. It must have a fail-safe mechanism to direct the user to human help if the AI service fails. * **Accessibility:** Non-voice/human-assisted alternatives must remain available for participants unable or unwilling to use voice-enabled assessment. ### **5. Actionable Implementation Checklist** * [ ] **Load Parameters:** Ensure the agent is initialized with the correct participant ID, designated index joint, and authorized WOMAC version. * [ ] **Validate Mapping:** Spoken responses must map strictly to authorized WOMAC options; if mapping confidence is low, the agent must prompt for manual confirmation. * [ ] **Segregate Data:** Keep raw voice/expression data separate from authoritative clinical response data. * [ ] **Audit Readiness:** Verify that the system saves both the initial participant response and any post-intervention confirmed response to the audit log.

Remote Cardiac Monitoring in Heart Failure Patients (HeartWatch-HF): PATIENT POPULATION: - NYHA Functional Class II-III heart failure - Chronic heart failure diagnosis - On standard medical therapy KEY MONITORING PARAMETERS: - Daily Weight: Report >3 lbs gain in 24 hours or >5 lbs in 1 week - Heart Rate: Normal range 60-100 bpm, alert if >100 or irregular - Blood Pressure: Target <130/80, alert if SBP >160 or <90 - Respiratory Rate: Alert if >22 breaths/minute - ECG Changes: New arrhythmias, ST changes, prolonged QT interval DECOMPENSATION WARNING SIGNS: - Increased shortness of breath at rest or minimal exertion - Orthopnea or paroxysmal nocturnal dyspnea - Progressive peripheral edema - Unusual fatigue or exercise intolerance - Rapid or irregular heartbeat - Confusion or altered mental status ACUTE RED FLAGS - IMMEDIATE MEDICAL ATTENTION: - Chest pain or pressure - Severe dyspnea at rest - Syncope or severe dizziness - Sustained rapid heart rate >120 bpm - SBP <90 or >180 mmHg - Loss of consciousness MEDICATION ADHERENCE FOCUS: - ACE inhibitors/ARBs: Monitor for cough, watch potassium - Beta-blockers: NEVER abruptly discontinue - Diuretics: May need dose adjustment with weight changes - Aldosterone antagonists: Check potassium levels regularly LIFESTYLE MANAGEMENT: - Fluid restriction: typically 1.5-2L per day - Sodium restriction: <2g daily - Regular light activity as tolerated (walking) - Elevate head of bed for orthopnea - Avoid excessive alcohol and caffeine PRIMARY STUDY ENDPOINTS (90+ days): - Hospital readmission reduction - Mortality rates - Quality of life improvement (KCCQ score) - Healthcare cost reduction - Patient satisfaction with remote monitoring

Based on the protocol for the HERALD (CV-NCOV-004) study, the following summary focuses on actionable thresholds set by trial staff and the required interventions when these thresholds are exceeded. ### 1. Safety Stopping and Pausing Thresholds Staff must monitor for specific events that trigger immediate cessation of dosing or trial-wide pauses: * **Individual Subject Stopping Rules:** A subject **must not** receive the second vaccine dose if they experience: * An allergic or anaphylactic reaction considered related to the trial vaccine. * Any Serious Adverse Event (SAE) considered related to the trial vaccine. * **Trial-Wide Pausing Rules:** The trial will be paused for a safety review by the Data and Safety Monitoring Board (DSMB) if staff detect: * Suspected Unexpected Serious Adverse Reactions (SUSARs). * Any safety signals, including signals of Vaccine-dependent Disease Enhancement (VDE). * Life-threatening AEs or deaths. ### 2. Clinical and Physiological Thresholds Staff are required to manage interventions based on the following specific measurement limits: * **Fever Thresholds:** * **≥ 38.0°C (100.4°F):** Vaccination **must be delayed** if this temperature is recorded within 3 days prior to intended vaccination. Vaccination can only proceed once the temperature is < 38.0°C. * **Grade 3 Fever:** Defined as **≥ 39.0°C**. This is a "Severe" event requiring immediate reporting to the Investigator. * **Oxygen Saturation (SpO2):** * **≤ 93% (on room air):** Threshold for **Severe COVID-19**; requires urgent clinical assessment. * **≥ 95% (on room air):** Threshold for **Mild COVID-19** (provided other symptoms are met). * **93% to < 95%:** Classified as **Moderate COVID-19**. * **Respiratory and Heart Rate:** * **Respiratory Rate (RR) ≥ 30 breaths/min:** Threshold for **Severe COVID-19**. * **Heart Rate (HR) ≥ 125 beats/min:** Threshold for **Severe COVID-19**. * **Moderate COVID-19 RR:** 20 to < 30 breaths/min. * **Blood Pressure (Shock):** * **Systolic BP < 90 mmHg** or **Diastolic BP < 60 mmHg** indicates evidence of shock (Severe COVID-19 criteria). ### 3. Adverse Event (AE) Severity Thresholds (Grade 3/Severe) Staff must intervene or escalate reporting when AEs reach Grade 3: * **Local Reactions:** Redness, swelling, or injection site pain **> 10 cm** or preventing daily activity. * **Systemic Reactions:** Nausea/vomiting requiring IV hydration; diarrhea **≥ 6 stools/24 hours**; or any symptom that "prevents normal everyday activities." * **Reporting Timeline:** Any SAE or Adverse Event of Special Interest (AESI) must be reported to the CRO **within 24 hours** of staff becoming aware of the event. ### 4. Eligibility and Medication Thresholds * **Corticosteroid Use:** Exclusion if treatment exceeds **0.5 mg/kg/day** of prednisone (or equivalent) for **> 14 days** within 6 months of vaccination. * **Vaccine Timing Window:** Licensed vaccines must not be administered within **28 days (live)** or **14 days (inactivated)** of the trial vaccine. If this threshold is crossed, trial vaccination should be rescheduled. * **Body Mass Index (BMI):** High-risk COVID-19 status is triggered at a **BMI ≥ 30 kg/m²**. ### 5. Trial Conduct and Regulatory Accrual Thresholds Staff and the DSMB monitor efficacy and futility based on "case-driven" accrual thresholds: * **Interim Analysis 1:** Triggered at **56 cases**. * **Early Success:** ≤ 9 cases in the CVnCoV group (VE ≥ 80.9%). * **Futility:** ≥ 25 cases in the CVnCoV group (VE ≤ 19.4%). * **Interim Analysis 2:** Triggered at **111 cases**. * **Early Success:** ≤ 32 cases in the CVnCoV group (VE ≥ 59.5%). * **Futility:** ≥ 40 cases in the CVnCoV group (VE ≤ 43.7%). * **Final Analysis:** Triggered at **160 cases**. Efficacy is demonstrated if ≤ 53 cases are in the vaccine group. ### 6. Intervention Protocols for Suspected COVID-19 If a subject reports symptoms (e.g., Fever ≥ 37.8°C, chills, or new cough), staff must: 1. Conduct a **scripted interview** (Appendix 6). 2. Provide a **thermometer and SpO2 monitor** for home use if the subject is symptomatic. 3. Instruct the subject to take readings **3–4 times per day**. 4. Perform a **Rapid Antigen Test** and a **central RT-PCR** (definitive test) within 5 days of symptom onset.

TRIUMPH Study - MTX-402 for Treatment-Resistant Depression: MEDICATION DETAILS: - Drug: MTX-402 (NMDA receptor modulator) - Indication: Treatment-resistant major depressive disorder - Mechanism: Modulates glutamatergic neurotransmission - Study Duration: 12 weeks DEPRESSION SEVERITY ASSESSMENT (MADRS): - <10: Normal mood - 10-34: Mild depression - 35-59: Moderate to severe depression - >60: Very severe depression TREATMENT RESPONSE DEFINITIONS: - Partial Response: ≥25% MADRS reduction - Significant Response: ≥50% MADRS reduction - Remission: MADRS score ≤10 SAFETY MONITORING REQUIREMENTS: - CRITICAL: Suicidal ideation assessment at every visit - Columbia-Suicide Severity Rating Scale (C-SSRS) administration - Liver function tests at baseline and week 6 - ECG monitoring per protocol schedule - Serious adverse event reporting within 24 hours CO-MEDICATION MANAGEMENT: - Current antidepressants may be continued per protocol - Screen for serotonin syndrome with SSRIs - Document all concomitant medications - Avoid abrupt discontinuation of study drug SECONDARY OUTCOME MEASURES: - Quality of life assessment (SF-36) - Functional disability evaluation (WHODAS) - Remission rates tracking - Time to response analysis CLINICAL CONVERSATION GUIDANCE: - Validate patient experience with treatment resistance - Encourage hope while maintaining realistic expectations - Monitor for emerging suicidal thoughts regularly - Reinforce medication adherence importance

Chronic Heart Failure Clinical Information: NYHA FUNCTIONAL CLASSIFICATION: - Class II: Symptoms with moderate exertion - Class III: Symptoms with minimal exertion KEY MONITORING PARAMETERS: - Daily Weight: Report >3 lbs gain in 24 hours or >5 lbs in 1 week - ECG Abnormalities: New arrhythmias, ST changes, prolonged QT - Vital Signs: HR >100, SBP <90 or >160, RR >22 HEART FAILURE DECOMPENSATION SIGNS: - Increased shortness of breath at rest - Orthopnea or paroxysmal nocturnal dyspnea - Peripheral edema worsening - Fatigue and exercise intolerance - Rapid/irregular heartbeat MEDICATION REMINDERS: - ACE inhibitors/ARBs: Monitor for cough, hyperkalemia - Beta-blockers: Don't abruptly discontinue - Diuretics: May need dose adjustment with weight changes - Aldosterone antagonists: Check potassium levels RED FLAGS FOR IMMEDIATE CONTACT: - Chest pain or pressure - Severe dyspnea at rest - Syncope or severe dizziness - Sustained rapid heart rate >120 - Blood pressure concerns LIFESTYLE GUIDANCE: - Fluid restriction: typically 1.5-2L per day - Sodium restriction: <2g per day - Regular light activity as tolerated - Sleep elevation for orthopnea

Type 2 Diabetes Treatment Information: BLOOD GLUCOSE TARGETS: - Fasting: 80-130 mg/dL - Postprandial (2-hour): <180 mg/dL - HbA1c Goal: <7% for most patients CGM ALARM THRESHOLDS: - High Glucose Alert: >250 mg/dL (assess for DKA risk) - Low Glucose Alert: <70 mg/dL (mild hypoglycemia) - Critical Low: <54 mg/dL (severe hypoglycemia - immediate intervention required) HYPOGLYCEMIA MANAGEMENT: - Symptoms: Tremors, sweating, palpitations, confusion, weakness - Mild (70-54 mg/dL): 15g fast-acting carbs, recheck in 15 mins - Severe (<54 mg/dL): Glucagon injection if unable to take oral carbs INSULIN THERAPY NOTES: - Basal-bolus regimen for intensive control - Monitor for lipodystrophy at injection sites - Adjust doses based on carbohydrate intake and glucose trends DIETARY COUNSELING POINTS: - Consistent carbohydrate counting - Emphasis on whole grains and fiber - Limit simple sugars and processed foods - Coordinate meal timing with insulin administration